Seagen Announces Updated Results from Pivotal HER2CLIMB Tria

– Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months of Follow-Up –BOTHELL, Wash.--(BUSINESS WIRE)--#SABCS2021--Seagen Inc. (Nasdaq:SGEN) today announced the presentation...

Related Keywords

Canada , United States , United Kingdom , Boston , Massachusetts , California , Washington , Switzerland , Seattle , America , American , David Caouette , Nancyu Lin , Rogerd Dansey , Peggy Pinkston , Metastatic Breast Cancer Program , World Health Organization , Susanf Smith Center , Lab Abnormalities , Seagen Inc , Nasdaq , Exchange Commission , Corporate Communications , European Union , European Medicines Agency , American Cancer Society , Exploratory Analyses , Show Patients , Active Brain Metastases Treated , Survival Benefit After Additional , Antonio Breast Cancer Symposium , Chief Medical Officer , Important Safety Information , Response Evaluation Criteria , Solid Tumors , Positive Breast , United Kingdom Medicines , Healthcare Products Regulatory Agency , Middle East , Latin America , Important Safety , Fetal Toxicity , Hepatic Impairment , Prescribing Information , Quarterly Report , Vice President , Investor Relations ,